Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells

被引:97
作者
Fauconnet, S
Lascombe, I
Chabannes, E
Adessi, GL
Desvergne, B
Wahli, W
Bittard, H
机构
[1] Ctr Hosp Univ Jean Minjoz, Serv Urol & Androl, Hop St Jacques, F-25000 Besancon, France
[2] Ctr Hosp Univ Jean Minjoz, INSERM, F-25000 Besancon, France
[3] Ctr Hosp Univ Jean Minjoz, Serv Endocrinol & Oncol Mol, F-25000 Besancon, France
[4] Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland
关键词
D O I
10.1074/jbc.M200172200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The growth of any solid tumor depends on angiogenesis. Vascular endothelial growth factor (VEGF) plays a prominent role in vesical tumor angiogenesis regulation. Previous studies have shown that the peroxisome proliferator-activated receptor gamma (PPARgamma) was involved in the angiogenesis process. Here, we report for the first time that in two different human bladder cancer cell lines, RT4 (derived from grade I tumor) and T24 (derived from grade III tumor), VEGF (mRNA and protein) is differentially up-regulated by the three PPAR isotypes. Its expression is increased by PPARalpha, beta, and gamma in RT4 cells and only by PPARbeta in T24 cells via a transcriptional activation of the VEGF promoter through an indirect mechanism. This effect is potentiated by an RXR (retinoid-X-receptor), selective retinoid LG10068 providing support for a PPAR agonist-specific action on VEGF expression. While investigating the downstream signaling pathways involved in PPAR agonist-mediated up-regulation of VEGF, we found that only the MER inhibitor PD98059 reduced PPAR ligand-induced expression of VEGF. These data contribute to a better understanding of the mechanisms by which PPARs regulate VEGF expression. They may lead to a new therapeutic approach to human bladder cancer in which excessive angiogenesis is a negative prognostic factor.
引用
收藏
页码:23534 / 23543
页数:10
相关论文
共 64 条
[1]   FUNCTIONAL ANTAGONISM BETWEEN THE ESTROGEN-RECEPTOR AND FOS IN THE REGULATION OF C-FOS PROTOONCOGENE TRANSCRIPTION [J].
AMBROSINO, C ;
CICATIELLO, L ;
COBELLIS, G ;
ADDEO, R ;
SICA, V ;
BRESCIANI, F ;
WEISZ, A .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (11) :1472-1483
[2]  
Auwerx J, 1999, CELL, V97, P161
[3]   Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice [J].
Berger, J ;
Bailey, P ;
Biswas, C ;
Cullinan, CA ;
Doebber, TW ;
Hayes, NS ;
Saperstein, R ;
Smith, RG ;
Leibowitz, MD .
ENDOCRINOLOGY, 1996, 137 (10) :4189-4195
[4]   Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects [J].
Berger, J ;
Leibowitz, MD ;
Doebber, TW ;
Elbrecht, A ;
Zhang, B ;
Zhou, GC ;
Biswas, C ;
Cullinan, CA ;
Hayes, NS ;
Li, Y ;
Tanen, M ;
Ventre, J ;
Wu, MS ;
Berger, GD ;
Mosley, R ;
Marquis, R ;
Santini, C ;
Sahoo, SP ;
Tolman, RL ;
Smith, RG ;
Moller, DE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6718-6725
[5]   Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer [J].
Bernardini, S ;
Fauconnet, S ;
Chabannes, E ;
Henry, PC ;
Adessi, G ;
Bittard, H .
JOURNAL OF UROLOGY, 2001, 166 (04) :1275-1279
[6]  
BROWN LF, 1993, AM J PATHOL, V143, P1255
[7]   ESTABLISHED CELL LINE OF URINARY-BLADDER CARCINOMA (T-24) CONTAINING TUMOR-SPECIFIC ANTIGEN [J].
BUBENIK, J ;
BARESOVA, M ;
VIKLICKY, V ;
JAKOUBKOVA, J ;
SAINEROVA, H ;
DONNER, J .
INTERNATIONAL JOURNAL OF CANCER, 1973, 11 (03) :765-773
[8]  
Celis JE, 1996, CANCER RES, V56, P4782
[9]   Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells [J].
Chabannes, E ;
Fauconnet, S ;
Bernardini, S ;
Wallerand, H ;
Adessi, GL ;
Bittard, H .
CELLULAR SIGNALLING, 2001, 13 (08) :585-591
[10]   Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells [J].
Chin, K ;
Kurashima, Y ;
Ogura, T ;
Tajiri, H ;
Yoshida, S ;
Esumi, H .
ONCOGENE, 1997, 15 (04) :437-442